TRIB1 constitutes a molecular link between regulation of sleep and lipid metabolism in humans by Ollila, Hanna Maria et al.
TRIB1 constitutes a molecular link between regulation
of sleep and lipid metabolism in humans
HM Ollila1,2,3, S Utge1,2,3, E Kronholm4, V Aho2, W Van Leeuwen2,5, K Silander1, T Partonen6, M Perola1, J Kaprio1,6,7, V Salomaa1,
M Sallinen5,8, M Ha¨rma¨5, T Porkka-Heiskanen2 and T Paunio1,3,6
Epidemiological studies show association between sleep duration and lipid metabolism. In addition, inactivation of circadian
genes induces insulin resistance and hyperlipidemia. We hypothesized that sleep length and lipid metabolism are partially
controlled by the same genes. We studied the association of total sleep time (TST) with 60 genetic variants that had previously
been associated with lipids. The analyses were performed in a Finnish population-based sample (N¼ 6334) and replicated in
2189 twins. Finally, RNA expression from mononuclear leucocytes was measured in 10 healthy volunteers before and after
sleep restriction. The genetic analysis identified two variants near TRIB1 gene that independently contributed to both blood lipid
levels and to TST (rs17321515, P¼ 8.92*105, Bonferroni corrected P¼ 0.0053, b¼ 0.081 h per allele; rs2954029, P¼ 0.00025,
corrected P¼ 0.015, b¼ 0.076; Po0.001 for both variants after adjusting for blood lipid levels or body mass index). The finding
was replicated in the twin sample (rs17321515, P¼ 0.022, b¼ 0.063; meta-analysis of both samples P¼ 8.1*106, b¼ 0.073).
After the experimentally induced sleep restriction period TRIB1 expression increased 1.6-fold and decreased in recovery phase
(P¼ 0.006). In addition, a negative correlation between TRIB1 expression and slow wave sleep was observed in recovery from
sleep restriction. These results show that allelic variants of TRIB1 are independently involved in regulation of lipid metabolism
and sleep. The findings give evidence for the pleiotropic nature of TRIB1 and may reflect the shared roots of sleep and
metabolism. The shared genetic background may at least partially explain the mechanism behind the well-established
connection between diseases with disrupted metabolism and sleep.
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Introduction
A previously unknown association between sleep and lipid
metabolism has started to emerge, based on epidemiological,
human experimental, and human genetics data as well as
data from animal models. Epidemiological studies show that
deviation from mid-range sleep length (7–8 h per night)
associates to several metabolic diseases with changed lipid
profile1 and even to increased mortality.2 Experimental sleep
restriction studies on humans demonstrate that shortening of
sleep reduces the utilization of lipids as energy source.3
Genome-wide association studies (GWAS) on blood lipid
levels, obesity and type 2 diabetes have identified risk variants
from genes that have traditionally been related to psychiatric
traits and sleep regulation, such as melatonin receptor 1 B
(MTNR1B),4 brain-derived neurotrophic factor (BDNF)5 and a
circadian pace maker gene cryptochrome 2 (CRY2).6 Mice
lacking circadian genes CLOCK or BMAL1 manifest altered
triglyceride and cholesterol metabolism and develop diabetes,
obesity and metabolic syndrome.7–10 Furthermore, in Droso-
phila, knocking out one of the key circadian genes, cycle,
leads to increased triglyceride levels, increased waking and
intolerance for sleep deprivation, demonstrating that sleep
homeostasis has a role in the regulation of lipid metabolism in
this species.11
Sleep length and blood lipid levels are regulated by a strong
genetic component. Electroencephalography spectra mea-
sured at 8–16 Hz frequency range during sleep shows
heritability of 96%,12 and self- reported sleep length has been
estimated to have heritability of 44% in a Finnish study of 6783
twin pairs.13 Recent GWAS studies have revealed that known
genetic variants explain 25–30% of the individual differences
in blood lipid levels at population level.14 Some of these
variants belong to genes that have previously been related to
lipid metabolism, such as apolipoproteins or LDL-C receptor
genes, whereas others are less obvious and are also
expressed in the central nervous system. The latter group
includes variants in the TRIB1 gene, which mediates the
MAPK signaling cascades,15 which is activated during
inflammation16 and participates in the regulation of cell cycle
progression.17 Most of the variants affecting blood lipids have
now been replicated and established in several populations,
even though the effect size of an individual variant alone is
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usually relatively small. The question whether the same gene
variants that affect blood lipid levels would also have an effect
on sleep duration has remained unexplored.
The aim of the present study was to elucidate the potentially
shared genetic component in sleep regulation and metabo-
lism. We examined the association of 60 previously identified
lipid gene variants18–21 with sleep length in a population-
based sample. We also addressed the question whether the
association between lipid trait variants and total sleep
time (TST) would be mediated through blood lipid levels. In
order to study the functional role of the identified gene variant
in regulation of sleep homeostasis, we measured the
expression of TRIB1 in healthy volunteers after they had
been exposed to partial sleep restriction (4 h per night) for 5
days. The analyses revealed that variants of the TRIB1
gene were independently associated with sleep length and
lipid metabolism. Restriction of sleep increased the gene
expression of TRIB1 indicating that it may be involved in
regulation of sleep homeostasis.
Materials and methods
Study design. The association of TST with four lipid traits,
triglycerides (TG), high-density lipoprotein (HDL-C), low-
density lipoprotein (LDL-C) and total cholesterol (TC) was
tested in a Finnish population-based sample set. After
revealing a connection between lipid levels and TST, SNPs
that had previously been shown to associate with TG, HDL-C,
LDL-C or TC were selected for the genetic association
analysis. We correlated these SNPs with TST and other
sleep-related traits in our Finnish population-based samples
and aimed for replication of our most significant finding in an
independent Finnish twin sample. Finally, the expression
levels of the gene highlighted in the genetic association
analysis was assessed in a sample of healthy individuals that
were subjected to cumulative sleep loss.
Study participants. A description of the cohorts is presented
in Table 1. The study was performed by combining data from
two population-based cohorts from Finland. The first cohort,
Health 2000 study (http://www.terveys2000.fi), is a nationwide
interview and health examination study performed from 2000–
2001. The participants of the Health 2000 study were selected
from the national population register so that they would reflect
the main demographic distributions of the Finnish population.
The participants were over 30 years of age and were
characterized for their health by home interview including
questions on their quality and duration of sleep and questions
concerning mental and general health. A health examination,
including laboratory examinations, was conducted at a
local health center, where blood samples for DNA extraction
and measurements of lipid levels were taken. Altogether,
Health 2000 comprised 8028 individuals, of which 6269
returned the questionnaire containing questions about sleep
length.
The second cohort was the nationwide interview and health
examination study FINRISK 2007 collected in 2007 (http://
www.ktl.fi/finriski). For this study a random sample of adults in
five regions of Finland was drawn from the Finnish national
population register.22 This study comprised altogether 7993
individuals aged 25–74 years. In this sample, genotype
information was derived from a GWA study carried out for
635 participants from the Helsinki area and described in
Inouye et al.23
The Finnish Twin Cohort, here used as replication sample,
was compiled from the Finnish national population register
and consisted of virtually all same-sex twin pairs born in
Finland before 1958 and with both co-twins alive in 1974.
Among them we identified 2189 individuals of 20–69 years of
age with both phenotype and genotype information (with
phenotype assessment from questionnaires given in 1975 or
1981).24
The experimental study consisted of 19 healthy men
(age 19–29) with habitual sleep duration of 7–9 h. They
were subjected to sleep restriction of 4 h of time in bed per
night for 5 nights. Nine of them were treated as controls
with 8 h of sleep per night during the whole study. After the
fifth day of the study the sleep-deprived subjects were
allowed to recover from the restriction for 2 nights with 8 h of
time in bed.
The ethics committee of Helsinki and Uusimaa Hospital
District approved the study protocol and informed consent
was obtained from all the participants. All participants
provided written informed consent for the collection of
samples and subsequent analysis.
Measures. For the metabolic analysis in the Finrisk sample,
TC was measured with the CHODPAP-assay (Abbott
Laboratories, Abbott Park, IL, USA), HDL-C with a direct
enzymatic assay (Abbott Laboratories) and TG with the
enzymatic GPO assay (Abbott Laboratories). In the Health
2000 sample HDL-C, TC and TG were measured using
enzymatic assays (Roche Diagnostics, Mannheim, Germany,
for HDL-C; Olympus System Reagent, Hamburg, Germany,
Table 1 Study subjects of Finnish samples
Cohort N N
(males)
N
(females)
Age
(years±SD)
TST
(h±SD)
TC (mmol l–1
±SD)
HDL-C (mmol l–1
±SD)
LDL-C (mmol l–1
±SD)
TG (mmol l–1
±SD)
Health 2000 5948a 2630 3318 54.22±16.2 7.49±1.22 5.93±1.12 1.32±0.38 3.77±1.19 1.62±1.05
FINRISK2007 6092b 2846 3246 50.80±14.3 7.64±1.21 5.25±1.00 1.44±0.37 3.16±0.87 1.44±0.95
Finnish twin
sample
2189 1024 893 44.08±6.09 7.96±3.67 NA NA NA NA
Abbreviations: HDL-C, high-density lipoprotein; LDL-C, low-density lipoprotein; TC, total cholesterol; TG, triglyceride; TST, total sleep time.
aAll individuals included in the genetic analysis.
bOverall, 635 individuals included in genetic analysis.
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for TC and TG). Sleep length was evaluated with a similar
question in all three cohorts: ‘How many hours do you sleep
per day?’. In addition to TST, we assessed the chronotypes of
the individuals using questions 4, 7, 9, 15,17 and 19 derived
from the morningness–eveningness questionnaire.25 In the
twin sample, chronotype was assessed by asking ‘Try to
estimate, whether you are a morning- or evening-type person’
and the answers were given as clearly morning-type, a bit
morning-type, a bit evening-type, clearly evening-type. The
individuals were assigned as morning-type, evening-type or
neither of the extreme types (N¼ 635, in FINRISK and
N¼ 2089 in Twin sample in the year 1981 questionnaire). The
analysis was performed so that the morning or evening types
were compared with the neither type group. Daytime dozing
was measured in Health 2000 sample using the Finnish
version of Epworth sleepiness scale (ESS),26 which com-
prised eight questions: How easily you fall asleep when (1)
sitting and reading (2) watching television (3) sitting inactive in
a public place (4) as a passenger for an hour in a car (5) lying
down to rest in the afternoon (6) when talking with someone
(7) when the car is stopping at traffic lights (N¼ 5981, 2706
males, 3275 females). Fatigue was assessed from the same
individuals in Health 2000 with a question: ‘Are you more tired
during the day than other people of your age?’
Genotyping and SNP selection. The SNPs were selected
based on their previous association from GWAS either with
TC, HDL-C-C, LDL-C-C or TG (Supplementary Table 1).18–21
The genotype data from Health 2000 and FINRISK2007
projects were obtained from the respective projects and were
originally genotyped using Sequenom Massarray technology
(San Diego, CA, USA) or Illumina 610 K platform (Illumina,
San Diego, CA, USA). In quality-control SNPs showing a
success rate over 95%, minor allele frequency over 0.1 and
Hardy–Weinberg equilibrium P41*103 were kept in the
analysis. Two variants were excluded in the quality-control
phase due to low Hardy–Weinberg P-value (rs150908 and
rs1289742).
Statistical analysis. In the epidemiological analysis the
individuals were divided into six groups based on TST (p5 h,
6 h, 7 h, 8 h, 9 h and X10 h). The association with TST and
lipid traits was tested using general linear model. The
analyses were performed using PASW Statistics 18 and all
analyses were adjusted for relevant covariates. These
included age, gender, lipid medication, hypnotics, body
mass index (BMI) and cohort.
In the genetic association analysis TST, Epworth sleepi-
ness scale and the lipid variables TC, HDL-C, LDL-C and
TG were analyzed as quantitative traits using a linear
regression model. For categorical variables (fatigue and
morningness–eveningness scale) a logistic regression model
was applied. In addition, short sleep (p6 h sleep) was
analyzed against the 7–8 h sleep group. All individuals
with information of their sleep length and genotype were kept
in the analysis. All analyses were adjusted for age and
gender. The lipid variables and ESS values were squared in
order to obtain normal distribution. The genetic association
analyzes were conducted using PLINK27 version 1.07 from
http://pngu.mgh.harvard.edu/purcell/plink/ (Boston, MA,
USA). The twin sample was analyzed using PLINK’s qfam
option with 1000 permutations. We judged the association by
P-value and b and the results were considered significant
when Bonferroni-corrected P-value for each SNP was
Po0.05.
Sleep restriction and RNA expression analysis. The
RNA expression analysis was performed as part of another
study.28 In short, the participants with a regular sleep-wake
schedule and habitual sleep duration of 7–9 h participated in
the study. During the experiment the experimental group
spent 8 h in bed for the first 2 nights (baseline (from 11 PM to
7 AM)), followed by 5 nights where they rested for only 4 h in
bed (sleep restriction (from 3 AM to 7 AM)) and, finally, again
2 nights of 8 h in bed (recovery). Continuous electroen-
cephalography recordings and a continuously present
investigator served to monitor that the participants did not
nap during the experiment. Meals were standardized and
energy-balanced based on the current national recommen-
dations, provided at fixed times and consumed by all
participants throughout the experiment. The study design
was approved by the ethics committee of Helsinki University
Central Hospital and a written informed consent was
obtained from participants. The experiment was conducted
at the Brain and Work Research Centre of the Finnish
Institute of Occupational Health.
RNA was collected from blood mononuclear leucocytes in
the morning after baseline, restriction and in recovery phases.
The RNA expression levels were tested using Affymetrix U133
Plus 2.0 human genome expression arrays (Affymetrix, Santa
Clara, CA, USA). Student’s t-test was used for calculating
significance values between the time points, repeated mea-
sures ANOVA was used to detect changes during the whole
sleep restriction experiment and fold changes were used for
estimating the magnitude of changes in expression levels. Slow
wave sleep (SWS) was scored manually. The values from
sleep restriction and recovery time points were normalized to
baseline values. Linear regression model was applied to
calculating the significance between baseline-normalized
TRIB1 RNA expression levels and baseline-normalized SWS
values in deprivation and recovery time points.
Results
Sleep length and blood lipid levels. The distributions of
the lipid levels across self-reported sleep duration are
shown in Table 2. Individuals having extremely short (p5 h
per day) or long sleep (X10 h per day) had the most
unfavorable lipid profiles as TG and TC levels were higher
and HDL-C levels were lower than in other groups. However,
LDL-C levels were lowest in the long sleepers. The
unadjusted and adjusted associations of sleep duration with
lipid levels were significant in general linear models Po0.001
(Table 3). However, sleep length explained only a small
percentage of the variation within the studied traits (Table 3).
Association of lipid trait SNPs with TST, replication and
meta-analysis. We then elucidated the role of 60 SNPs
previously defined as significant genetic determinants for
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blood lipid levels by GWAS18–21 and associated them with
sleep duration. Two significant association signals down-
stream of TRIB1 gene were observed with TST (rs17321515,
P¼ 8.92*105, b¼ 0.081; rs2954029, P¼ 0.00025, b¼ 0.076,
corrected P¼ 0.0053 and P¼ 0.015, respectively) with the
protective minor allele ‘G’ and ‘T’. The percentages of
genotypes for rs17321515 in the TST groups are presented
in Table 4.
In addition, the same variants associated significantly with
blood lipid traits and both TRIB1 SNPs showed the strongest
association with blood TC levels (rs17321515, P¼ 1.45*105,
b¼1.004 and rs2954029, P¼ 4.62*105, b¼0.95). The
variant rs2954029 that originally associated with blood TG
levels was only nominally significant here (P¼ 0.029,
b¼0.29). However, the associations of both SNPs with
TST remained significant after adjustment for TG, TC, HDL-C,
LDL-C levels or BMI (for all analyses Po0.05). Similarly, the
association of TRIB1 SNPs with TC remained significant after
adjustment for sleep duration (TC Po0.05 for both variants),
whereas the signal of rs2954029 with TG was lost when
adjusted with TST. The effect size in healthy individuals was
largest among those having 6 h or shorter sleep duration. The
findings are in line with a recent publication where the
heritability for fat mass index and BMI were higher in
individuals having short sleep duration, suggesting that the
genetic component of lipid metabolism is largest among those
having short sleep duration.29 The original P-values for all
tested SNPs including suggestive significant variants are
listed in Supplementary Table 1 and the association analysis
of 17321515 and rs2954029 with lipid levels in different TST
groups are presented in Supplementary Table 2.
The risk allele ‘A’ of rs17321515, originally associated with
higher blood TC in GWAS for blood lipid levels19 was found to
associate with shorter sleep length (P¼ 0.04, OR¼ 1.109,
95% CI¼ 1.004–1.22 in dichotomous analysis). In addition,
individuals having genotype major/major AA of rs17321515
had the shortest mean sleep length (Figure 1a) and the
frequency of this genotype was highest in the individuals
sleeping o7 h (Figure 1b). Furthermore, the major/major AA
individuals had the shortest sleep duration in all age groups
throughout the data when compared with individuals carrying
AG or GG genotypes (Figure 1c). The tightly linked variants
rs17321515 and rs2954029 in TRIB1 (D0 ¼ 0.998 and
R-Sq¼ 0.957) were possibly tagging the same position.
There was no interaction of gender or age and TST with
either of the TRIB1 variants (analysis of interaction with
gender and age P40.05). In order to study the variants in
Table 2 Mean±SD values of laboratoric measures of four different lipid traits in the sleep length groups
Total sleep
time (hours)
N TG mmol l–1±SD TC mmol l–1±SD HDL-C mmol l–1±SD LDL-C mmol l–1±SD
p5 370 1.63±1.04a 5.77±1.08b 1.36±0.41 3.61±1.145a
6 1327 1.57±1.04a 5.65±1.12a 1.38±0.39 3.51±1.11
7 4101 1.48±0.97b 5.61±1.11b 1.39±0.38 3.5±1.08b
8 4472 1.50±0.96 5.57±1.11b 1.39±0.38 3.45±1.09b
9 1208 1.53±1.00 5.48±1.07c 1.39±0.37 3.37±1.01c
X10 562 1.79±1.28c 5.57±1.20 1.31±0.39c 3.36±1.17a
Total 12 040 1.52±1.00 5.59±1.11 1.38±0.38 3.47±1.09
Abbreviations: HDL-C, high-density lipoprotein; LDL-C, low-density lipoprotein; TC, total cholesterol; TG, triglyceride.
aANOVA P-valueo0.05 indicates significant association with sleep duration when comparing the group to all other sleep duration groups within the lipid variable.
bANOVA P-valueo0.01 indicates significant association with sleep duration when comparing the group to all other sleep duration groups within the lipid variable.
cANOVA P-valueo0.001 indicates significant association with sleep duration when comparing the group to all other sleep duration groups within the lipid variable.
Table 3 GLM model of TST and lipid levels
Trait N with
data
Model unadjusted Model adjusted for age and gendera Model 3b
Unadjusted
effect of
sleep duration
The whole
model
Independent
effect of sleep
duration
The whole
model
Independent
effect of sleep
duration
df F P R2 N with
data
df F P R2 F P N with
data
df F P R2 F P
TC 12 040 5 5.626 o0.001 0.002 12 040 9 65.489 o0.001 0.036 5.409 o0.001 9763 11 156.25 o0.001 0.149 2.428 0.033
HDL-C 12 040 5 5.461 o0.001 0.002 12 040 9 205.99 o0.001 0.106 6.29 o0.001 9763 11 160.96 o0.001 0.153 4.082 0.001
LDL-C 12 039 5 5.589 o0.001 0.002 12 039 9 53.146 o0.001 0.029 7.166 o0.001 9762 11 144.59 o0.001 0.139 2.523 0.027
TG 12 040 5 12.028 o0.001 0.005 12 040 9 94.015 o0.001 0.051 9.258 o0.001 9763 11 77.202 o0.001 0.079 4.34 0.001
Abbreviations: HDL-C, high-density lipoprotein; LDL-C, low-density lipoprotein; TC, total cholesterol; TG, triglyceride.
aModel 2 adjusted for age, sex.
bModel 3 adjusted for age, sex, BMI cohort, lipid medication and hypnotics.
Table 4 Genotype frequencies of rs17321515 in sleep length groups
(N¼6334)
Sleep length (hours) AA (%) AG (%) GG (%)
p5 3.93 3.53 3.68
6 13.58 10.92 10.83
7 36.21 36.18 33.16
8 35.14 36.86 38.47
9 7.74 8.71 9.65
X10 3.39 3.80 4.20
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healthy individuals without major sleep problems and high
cholesterol, we excluded individuals taking hypnotics or
lipid medication and performed the association analysis
with the two significant TRIB1 variants. We observed that
the association was still significant and the effect was
greater (rs17321515, P¼ 0.00067, b¼ 0.13 and rs2954029,
P¼ 0.00076, b¼ 0.13).
The finding on TRIB1 variant rs17321515 was replicated
in the twin sample with 2189 adult Finnish twins, where
we saw allelic replication (P¼ 0.022, b¼ 0.063, permuted
P¼ 0.031). The meta-analysis combining the population
cohort and twin sample further strengthened the original
association (P¼ 8.1*106, b¼ 0.073).
Association with other sleep-related traits. As a
secondary analysis, we examined the association of TRIB1
variants with other sleep-related traits. We found evidence
for association with sleepiness (rs17321515, P¼ 0.034,
b¼1.45, rs2954029, P40.05 to ESS) and eveningness
chronotype (rs17321515, P¼ 0.030, OR¼ 0.61, 95%
CI¼ 0.39–0.96, rs2954029, P¼ 0.026, OR¼ 0.60, 95%
CI¼ 0.38–0.94) but no association with fatigue (P40.05).
The association signal with ESS also remained significant
when adjusted for blood lipids (Po0.05). Individuals with the
minor allele for either variant were less evening-type, whereas
the risk alleles increased the eveningness chronotype.
However, we could not replicate the finding on eveningness
chronotype in the twin sample (P40.05).
TRIB1 RNA levels in sleep restriction. In order to elucidate
the role of TRIB1 in regulation of sleep homeostasis, we
studied the reaction of TRIB1 RNA levels to sleep restriction
(Figure 2). We found that the TRIB1 expression levels were
significantly higher in individuals subjected to sleep restriction
(TRIB1 fold increase of 1.6, Po0.05). The expression levels
returned back to baseline in the recovery phase (TRIB1 fold
decrease from deprivation to recovery 2.6, Po0.001) and the
overall change was significant based on repeated measures
ANOVA (P¼ 0.006). Finally, we performed analysis of
TRIB1 expression levels and SWS, where the amount of
SWS and Trib1 expression was normalized to baseline
levels. No association was seen in baseline vs deprivation
but a significant association with TRIB1 expression
and SWS was detected in the baseline to recovery
phase (P¼ 0.022, b¼1.05), suggesting a role for Trib1
in recovery sleep.
Discussion
We found independent association of two genetic variants
near TRIB1 gene with blood lipid levels and TST in 6334
adults from a population-based sample. The best finding,
rs17321515, was replicated in an independent sample of 2189
Finnish adult twins and meta-analysis of these two cohorts
further strengthened the association. We found association of
the risk allele ‘A’ with increased short sleep and increased TC
and TG levels. The association was strongest among
individuals that did not take hypnotics or lipid medication,
suggesting a role for TRIB1 in physiological sleep regulation.
Furthermore, an experimental sleep restriction study gave
functional evidence for the role of TRIB1 also in homeostatic
sleep regulation in healthy individuals as TRIB1 was
upregulated upon sleep restriction. The TRIB1 variants were
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earlier reported to associate with TC and TG levels18–21 and
we were able to confirm such an association. Recently, it was
shown that Trib1 regulates TG and VLDL levels also in mice.30
Surprisingly, the associations with sleep length and lipid
levels were independent from each other, and adjusting the
analysis of TST for lipid traits, or vice versa did not abolish the
association with the TRIB1 variants with either TST or lipid
traits. Here, the risk variants were related to shorter TST. In
addition to shorter sleep length, the individuals carrying the
risk allele of either of the studied variants scored higher on
sleepiness. They also scored higher in questions on the
eveningness chronotype, which has been related to many
adverse health-related phenomena such as smoking, alcohol
use, physical inactivity or depressiveness,31–33 as well as to
increased heart rate or blood pressure both at rest and during
stress.34 However, the finding on the eveningness chronotype
could not be replicated, which was possibly due to the single
item used to assess eveningness in the replication data set
whereas the original data set consisted of seven questions
measuring the chronotype or due to a relatively weak
association with eveningness in the original dataset, which
would have required a larger replication sample.
The risk variants associated with higher TC and earlier
TRIB1 variants have been associated with coronary artery
disease35 and metabolic syndrome.36 Short sleep length is
also a known risk factor for developing cardiovascular
diseases.37–40 The findings suggest that common genetic
factors may contribute both to short sleep and to diseases with
disrupted metabolic regulation. To our knowledge, this is the
first study to show that the same genetic variants are
associated with both sleep duration and with plasma lipid levels.
Earlier studies show significant correlation between sleep
duration and diseases with disrupted metabolism such as
cardiovascular diseases, diabetes and obesity.37–41 Short
sleep is also a predisposing factor for developing these
diseases. In concert with these earlier studies, we observed a
significant association between self-reported sleep length and
with all measured lipid traits: TG, TC, HDL-C and LDL-C after
adjusting for several confounders including age, sex, BMI,
study cohort, lipid medication and hypnotics. However, sleep
length explained only a small proportion of the total variation in
lipid levels. Our findings are in line with previous studies and
suggest that the previously described association of short and
long sleep length with cardiovascular diseases41 and mortal-
ity2 might be carried out by prolonged exposure to high TG
and low HDL-C levels. However, there may be also other
factors contributing to this association and this hypothesis
would need to be studied in longitudinal setting.
Finally, we studied the reaction of TRIB1 RNA levels to
sleep restriction. We observed an upregulation of TRIB1 RNA
levels after sleep restriction. The expression levels returned
back to baseline after the recovery phase. In addition, the
relative decrease in the Trib1 expression level in recovery was
associated with the relative increase in SWS in recovery
phase further suggesting a role for TRIB1 in the regulation of
sleep homeostasis. Interestingly, another protein from the
same family, TRIB2, has been found to have a role in the
pathogenesis of narcolepsy, a sleep disorder with symptoms
of daytime sleepiness.42 In addition, TRIB2 autoabtibodies
have been found in uveitis.43 TRIB1 and TRIB2 are part of the
same protein family and regulate similar signaling cascades
related to inflammation and Akt and MAPK signaling.15,44,45
Even though TRIB1 and TRIB2 share molecular signaling
properties, they are found in different physiological traits.
TRIB1 is related to energy metabolism and has been found in
lipid trait and coronary heart disease GWAS, whereas TRIB2
is related to inflammatory reactions and autoantibody produc-
tion in narcolepsy and uveitis. Furthermore, Trib1 and Trib2
are found in different cellular locations. Trib1 protein is
detected in the nucleus, whereas Trib2 is cytoplasmic
protein.45,46 In addition, TRIB2 has been shown to be a
negative regulator for innate immune reactions and monocyte
activation that have an important role in autoimmune
disorders.42,47 Interestingly, innate immune have also been
found to be activated upon sleep restriction.28
Trib1 is ubiquitously expressed with relatively high expres-
sion values in liver, blood leucocytes and brain.30 Studies in
Trib1 over expressing mice show that higher hepatic Trib1
expression lowers TG, VLDL, HDL-C and LDL-C levels and
APOB secretion, whereas in Trib1 knockout animals an
opposite effect is seen. The action of Trib1 on lipids in the
hepatic cells has been shown to be mediated through the
modulation of genes involved in lipid metabolism such as
acetyl-CoA carboxylase 1 (Acc1), fatty acid synthase (Fasn),
and stearoyl-coenzyme A desaturase1.30 Our results suggest
that the effect of Trib1 on TST is not directly dependent on lipid
levels. However, TST associates with cholesterol and
triacylglycerols in epidemiological studies, and experimental
sleep deprivation experiments in mice have shown that
transcription of genes regulating cholesterol synthesis and
lipid transport is increased during sleep.48 Recently, a sleep
deprivation study in Drosophila found a connection between
lipid metabolism and tolerance to sleep deprivation, suggest-
ing that alterations in lipid metabolism enzymes altered the
response to sleep deprivation.11 It is thus possible that the
association between Trib1, sleep and lipid levels is mediated
at least partially through the same genes. Another possible
mechanism linking Trib1 with sleep regulation is MAPK
signaling. This pathway is one of the key signaling cascades
affecting sleep and circadian rhythms49 and Trib1 has also
been shown to regulate MAPK signaling.15 The mechanism
could also involve the (inhibitory) effect of Trib on Akt
signaling43 and, subsequently, the circadian pacemaker and
the sleep–wake cycle, on sleep homeostasis.50 It is plausible
that Trib1 association with TST is mediated through the
interconnected regulation of sleep and metabolism. Elucida-
tion of the molecular mechanisms of Trib1 on sleep regulation
will require further studies applying both experimental animal
models and sleep studies in humans.
In this study, we have included a large sample from Finland
for both epidemiologic and genetic analysis. Compared with
other European populations, Finns are genetically a relatively
homogenous group,51 which makes them ideal for genetic
studies. A limitation of the study is that sleep was assessed
solely with questionnaires. Some studies have suggested that
self-reported sleep duration may somewhat overestimate the
amount of physiological sleep52,53 although this overestima-
tion may decline with longer sleep.52
To conclude, our results suggest that TRIB1 is a novel
factor regulating sleep duration and homeostasis. TRIB1 has
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a pleiotropic role in metabolic regulation as it associates with
several metabolic traits.36 Here, we observed its independent
association with both blood lipid levels and with TST in a
population-based sample from Finland, suggesting a pleio-
tropic nature for TRIB1 not only in metabolism but also in the
physiological mechanism of sleep regulation. The association
to TST was replicated in another population-based sample of
twins. After experimental sleep restriction of 5 nights in
healthy individuals, expression of TRIB1 was found to be
significantly increased and returned back to baseline in
recovery phase. In addition, the relative decrease in TRIB1
expression in recovery phase associated with the increase in
SWS further suggesting a role for TRIB1 in homeostatic sleep
regulation. To our knowledge, this is the first study to describe
a human metabolic gene variant that regulates both sleep and
metabolism. The finding may reflect the common roots of
these physiological processes. Furthermore, their shared
genetic background may at least partially explain the well-
established connection between diseases involving disrupted
metabolic processes, such as cardiovascular disease, obesity
and type 2 diabetes mellitus, and sleep.
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